-Mar-20 31-Mar-20 31-Dec-18 Interest bearing debt to equity (time) 2.84 1.10 0.56 Net interest bearing debt to equity (time) 2.21 0.47 0.20 Debt to equity (time) 3.70 1.96 1.22 31-Mar-20 31-Mar-20 31-Dec
www.interpharma.co.th 6. Approve to present to the Shareholders' Meeting to consider and approve the issuance of debentures in the amount not exceeding 300 million Baht. The total debt burden of the Company at any one
+ upload เอกสารประกอบ Filing (69-Debt-PO) มีผล 1,5,10 วันท าการ (แล้วแต่กรณี) ขาย รายงานการไถ่ถอน/ใช้สิทธิ รายงานผลการขาย Online พร้อม upload เอกสารประกอบ ไถ่ถอน/ใช้สิทธิ ภำยใน 15 วนันบัแต่สิน้เดือนที่เสนอ
purchase as 79,470 Baht per SQ.WA.which is the cheaper price than market value. 6. Criteria to determine the price The overall construction cost of Wattanapat Samui Hospital based on the project of
BIBOR 3-month plus percent of fixed rate per annum 2.2.4 Long-term debt of FPT under rehabilitation plan with Bangchak Petroleum Plc. was of Bt10.5 million. 2.2.5 The Employee benefit obligations was of
. This came from increment of number of staff to support new incoming projects. 6.2 Provision for doubtful debt decreased in amount of Baht 7.17 million due to payment received from the debtors 6.3 Other
December 2018 and 2017, the Group has the allowance for doubtful accounts, amounting to Baht 52 million and Baht 51 million, respectively. The Group’s policy on allowance for doubtful accounts is based on
PROGRESS OF PROJECTS UNDER CONSTRUCTION 3 * primarily include the construction revenue recognizes based on the percentage of completion of hydro power projects in Lao PDR which offset with the construction
Bt2.2 million at the rate of MLR minus percent of fixed rate per annum 2.2.4 Long-term debt of FPT under rehabilitation plan was of Bt3.8 million. 2.2.5 The Employee benefit obligations was of Bt1,134.9
transaction of purchasing FKRMM in Malaysia in 2019, so there is no remaining debt for this transaction. Please be informed accordingly, Yours faithfully, ............................................... (Mr